Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1239
- Registration Number
- NCT03085810
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇵🇱Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, Poland
🇺🇸Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT03084939
- Locations
- 🇨🇳
Beijing Hospital, Beijing City, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Changzhou First People's Hospital, Changzhou, China
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 860
- Registration Number
- NCT03075696
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
🇩🇰Rigshospitalet, København Ø, Denmark
A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- Other: No Intervention
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 84
- Registration Number
- NCT03071848
- Locations
- 🇦🇷
Hospital Julio C. Perrando, Chaco, Argentina
🇦🇷Policlínico regional de San Luis, San Luis, Argentina
🇦🇷Centro Medico San Roque, San Miguel de Tucuman, Argentina
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1101
- Registration Number
- NCT03072238
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: RO6870810Biological: daratumumab
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03068351
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Emory Uni - Winship Cancer Center; Hematology/Oncology, Atlanta, Georgia, United States
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
- Conditions
- Cancers With NTRK, ROS1, or ALK Gene Fusions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03066661
- Locations
- 🇺🇸
1-844-Startrk (782-7875), San Diego, California, United States
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT03063762
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇫🇷Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon, France
🇮🇹Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia, Modena, Emilia-Romagna, Italy
Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: Obinutuzumab
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT03059251
- Locations
- 🇦🇷
Clínica Peuyrredón, Buenos Aires, Argentina
🇦🇷Hospital Municipal Teodoro Alvarez, Buenos Aires, Argentina
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Expanded Access to RXDX-105 for Cancers With RET Alterations
- Conditions
- Cancers With RET Alterations
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03052569
- Locations
- 🇺🇸
Www.Ignyta.Com, San Diego, California, United States